Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Jeffrey, is this you?
https://en.m.wikipedia.org/wiki/Jeffrey_Dahmer
Cannabis Science Expands Cancer Portfolio to Include Leukemia Treatment
Research Utilizing Cannabinoid-Based Medicines GlobeNewswire "Press Releases"
IRVINE, CA , Jan. 31, 2018 (GLOBE NEWSWIRE) -- Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, announces that the Companys research team is expanding the scope of its current cancer research to include Leukemia.
As we gain increasing clarity of how cannabinoids work we will influence the development of drug delivery mechanisms, the use and dosage of appropriate cannabinoids, and the identification of target conditions, stated Dr. Allen Herman , CBIS Chief Medical Officer. Cannabis Science believes that cannabis extracts are critical instruments in cancer treatment and that we have an obligation to produce and make available the most effective and efficient Cannabis products to our anti-cancer modalities, stated Dr. Herman .
With 29 states now having Medical Marijuana laws and as many as six more on the ballots this coming year, Cannabis Science will continue its research and prepare to make available medication with a preferred delivery method to treat those suffering from Leukemia and potentially other cancers.
"Were sitting on the edge of tremendous innovation that will transform the landscape for providers, for patients, and for those companies bringing these products to market. The global market for cancer drugs has hit $100 billion in annual sales and could reach $147 billion by 2018, according to a new report by the IMS Institute for Healthcare Informatics , a unit of drug data provider IMS Health . The cost per month for a new cancer drug has increased 40%, or $5,900 , over the past decade. " says Mr. Raymond C. Dabney , President, CEO, and Co-Founder of Cannabis Science . As more and more states recognize the benefits of Medical Marijuana we will be there to aid the fight against cancers with our cost effective innovative Cannabis-based therapies.
This announcement comes out as CBIS has recently published initialresearch results on using nanoparticle drones to target lung cancer with radiosensitizers and cannabinoids in the cancer research journal,Frontiers in Oncology. The article can be viewed at:
https://www.frontiersin.org/articles/10.3389/fonc.2017.00208/full
Cannabis Sciences priority has always been to identify unique approaches using cannabinoids in the treatment of a range of cancers and other critical ailments. There is a growing body of evidence that demonstrates the effectiveness of cannabinoids in the treatment of cancer. These pharmacologic compounds act on both CB-1 and CB-2 receptors and limit inflammation, curb cell proliferation, and affect cell survival. There have been a number of substantial reviews of the progress and promise of cannabinoids as anti-cancer drugs.
The article is an initial result of burgeoning CBIS collaborative work and speaks to a key conclusion from the National Academies of Sciences , Engineering, and Medicine 2017 Report onThe health effects of cannabis and cannabinoids: Current state of evidence and recommendations for research.
This report can be viewed at:http://nationalacademies.org/hmd/reports/2017/health-effects-of-cannabis-and-cannabinoids.aspx
Research in cellular models has revealed that cannabis has some promising effects on leukemia. In 2005, a study by Powles et al. demonstrated that tetrahydrocannabinol (THC), the active metabolite of cannabis, induces apoptosis (programmed cell death) in leukemia cell lines as early as six hours following THC administration. The cannabinoids act as agonists in the endocannabinoid system by impacting the G protein coupled receptors (GPCR). These receptors play a central role in much of cell biology and influence cell organelles (e.g. mitochondria the powerhouses of the cell).
Leukemia places a substantial health burden on communities. Each year more than 27,000 adults and 2,000 children in the United States are diagnosed with leukemia. There are almost 390,000 persons living with leukemia and at 6.8 per 100,000 persons, it is the seventh leading cause of cancer deaths in the U.S.
About Cannabis Science , Inc.
Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
Forward-Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. , does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company is detailed from time to time in the company's reports filed with the Securities and Exchange Commission .
Contact Information: Cannabis Science, Inc. Dr. Allen Herman Chief Medical Officer allen.herman@cannabisscience.com 1-888-263-0832 Cannabis Science, Inc. Mr. Raymond C. Dabney President & CEO, Co-Founder raymond.dabney@cannabisscience.com 1-888-263-0832
Source: Cannabis Science, Inc.
Easy! I bet we are rubbing two nickels together in no time!
Gonna be doing some digging on this guy tonight and will post any new findings
I saw we got a new CEO
Losing a zero tomorrow fella's!
What a good day! No stopping this high speed train!
Someone is loading all the 0011's they can, next move up is gonna be BIG!
002 COMMETH SOON
As i suspected... just a dead cat bounce on friday...no volume here all week...T-trades yesterday...VNDM on the ask....ill be a buyer at no bid when everyone cashes out for their tax loss...
4's fall and this is gonna be a lot thinner! Lots of shares got shook this am! Going to be interesting to see how the rest of the day plays out!
Wont take long to get there, have a email out to management now, i suggest everyone else do the same!
Rag$
Trying to get all caught up, looks like we are churning nicely! I will check back in later! Looking forward to a nice run here!
Any idea how much dilution we got left? Has to be getting really close to being done. TIA
added more to my pile
I confirmed last week before I bought in, it is still the same!
I spent my saturday looking into the new accounting firm...I was very pleased with what I have found, big firm, have done several audits for companies that have done IPO's to nasdaq, great reputation etc! I will be patient with this one but i bet we lose a zero here pretty quick!
this moves on air! gonna lose a zero soon imo! Management so much as farts on a PR this is gonna run hard and fast! I personally like the slow nice walk up myself, new base is being formed for the next leg! Patience is gonna pay off BIG here imo!
Rag$
Ready for this bomb to explode!
Churning nice this morning, chart is starting to curl up! Should be a nice couple weeks here folks!
7 billion is a lot, I’m sure the otc markets site will update this change once they get the info unless they have a issue with the TA too.
I think I will sit this one out
Rag$
What’s the share structure here?
Next couple of weeks should be great here!
Ya'll see how big our new accountant is?? Article is from 2 weeks ago!
https://www.accountingtoday.com/news/deloitte-and-sadler-gibb-top-sec-audit-client-rankings
Stepping into oversold territory! Looking for a nice afternoon POP back up and retest of highs!
I confirmed it Wednesday as well, still accurate!
LOOK!
This 8-k filed in September
https://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=12275851
Hired
http://www.sadlergibb.com/
Look into them.... I like what I am seeing folks!!
Rag$
This may leave the trips today!
Exactly Raven! Slow and steady is so much better than the huge quick pops! Nice and controlled to the promise land! We will lose a 0 next week imo!
Rag$
Lunch has come and gone, same as these 6's will!
Love the nice stair step, lets just churn our way out of the trips! Slow and steady wins the race!!
Perfect storm brewing
This gonna rock! TA confirmed SS is the same, NO DILUTION! Next big runner!
Verified the SS with the TA yesterday, its the same as posted above here...No dilution! Float is gonna get locked up and we are gonna test VNDM at 003 before xmas! Should be a great ride here!
Rag$
Sounds like it to me!
Those shares are worth roughly 27 million as it stands today!
Small price to pay imo!
Once the company releases news/fins/filings, anything those defendants will have a lot more reasons to fight this thing out till the end! I think the court case will be resolved here shortly but thats just my opinion!
Rag$
I would rather them partner with a profitable company, like Long Star...oh wait...we already did that..
Patience folks
Rag$
Big banner we have here! And a Robot for you too Hawk!
http://overseas.weico.cc/share/10240848.html?weibo_id=4176295082308133
Rag$
What if their next filing shows enough juicy info to propel this to say the .15-.25 area? I bet it does imo
I am no legal expert, but if I was the defendants in the lawsuit and I saw my shares were worth now millions and millions of dollars I would be more inclined to fight the case and do whatever it takes to win....not to mention you could most definitely find a lawyer to work for a percentage opposed to upfront fee's with shares valued at such a high amount...with a higher PPS if the company wishes to settle out of court for the shares it would be much better for them if the PPS was lower as well.
I dont know if the court case has anything to do with their silence or lack of filings, but if it does, kinda makes sense to keep things hush until the case is settled which hopefully is sooner than later!
I wish I had 50M shares of this gold mine!
Rag$